'Cross-talk' mechanism contributes to colorectal cancer

November 13, 2009

Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.

"We are very excited about these findings," says Vladimir Spiegelman, an associate professor of dermatology. "Drugs could be developed to block this mechanism and prevent colorectal cancer, which affects millions of people worldwide."

The research will appear in the current (Nov. 15) Cancer Research.

Spiegelman and his team study cellular processes that produce several types of cancer. They have focused recently on the Wnt signaling pathway, which has been implicated in the vast majority of all colorectal cancers.

Like all signaling pathways, this one involves a group of molecules that work in sequence to perform a specific cell function. At each step along the way, the molecules perform tasks outlined in the signals until the job is finally done. If there's a breakdown anywhere in the normal process, cancer can occur.

In an earlier paper published in Nature, Spiegelman's team described how signals in the Wnt pathway regulate CRD-BP, a gene that contributes to normal colorectal cells' changing into .

"Within the Wnt pathway, we found that CRD-BP binds to and increases the messenger RNA of a cancer-promoting transcription factor called GLI1," Spiegelman explains.

The scientists knew that GLI1 was also active in another , called Hedgehog, which is known to be associated with the development of several kinds of cancers although its role in colorectal cancer has been controversial. So they explored how the two pathways interact around CRD-BP and GLI1 messenger RNA.

"Scientists have postulated that these two pathways engage in cross-talk in different ways, but the mechanisms of how and where that happens have been unclear," Spiegelman says. Each pathway, he adds, contributes in important ways to normal embryonic development and stem-cell maintenance.

The team found that CRD-PB serves as the link between the Wnt and Hedgehog pathways.

From the Wnt pathway, CRD-PB imposes itself on the Hedgehog pathway, stabilizing and dramatically increasing the expression of GLI1 there.

"This occurs irrespective of what happens upstream in the Hedgehog pathway," says Spiegelman. "Hedgehog signaling is not necessary for this to occur, even though the outcome mimics the activation of the Hedgehog pathway."

Increased GLI1 then activates cancer-promoting genes that are usually considered downstream targets of the Hedgehog pathway.

The findings point to promising therapeutic possibilities, says Spiegelman.

"GLI1 by itself could be an excellent target for a potential blocking drug," he says. "But if we go upstream and target CRD-PB, we can affect the two different signaling pathways even more effectively."

Source: University of Wisconsin-Madison (news : web)

Related Stories

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.